| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| GTO ID | GTC3450 |
| Trial ID | NCT05869955 |
| Disease | Systemic Lupus Erythematosus | Systemic Mycosis | Idiopathic Inflammatory Myopathy |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CC-97540 |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE) |
| Year | 2023 |
| Country | United States |
| Company sponsor | Bristol-Myers Squibb |
| Other ID(s) | CA061-1001|2023-503823-24 |
| Cohort 1 | |||||||||
|
|||||||||